Glenmark Launches Authorized Generic of Axitinib for Kidney Cancer in the US

Glenmark Launches Authorized Generic of Axitinib for Kidney Cancer in the US

Glenmark Pharmaceuticals has announced the US launch of an authorized generic version of Inlyta (axitinib), an oral targeted therapy used in the treatment of advanced renal cell carcinoma (RCC), the most common type of kidney cancer.

Announced on November 16, 2026, the launch introduces axitinib tablets in 1 mg and 5 mg strengths to the US market under a generic name. The product is an authorized generic of Pfizer’s Inlyta, which has been used in kidney cancer treatment since its initial FDA approval in 2012.

The development comes as the oncology community continues to address the financial burden of cancer treatment, particularly for patients requiring prolonged systemic therapy. While targeted therapies have expanded treatment options for advanced kidney cancer, medication costs and insurance coverage remain important considerations for patients and healthcare systems.

Glenmark’s launch represents a commercial expansion of an established cancer treatment rather than the introduction of a new therapeutic agent.

Axitinib and Its Role in Kidney Cancer Treatment

Axitinib is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2 and VEGFR-3). By inhibiting signaling pathways involved in angiogenesis, the drug interferes with the formation of blood vessels that support tumor growth.

The FDA-approved indications for the reference product, Inlyta, include its use in combination with pembrolizumab or avelumab as a first-line treatment for patients with advanced renal cell carcinoma.

Axitinib is also approved as a single agent for patients with advanced RCC whose disease has progressed following one prior systemic therapy.

These indications reflect the drug’s established role in kidney cancer management, where VEGF-targeted agents and immune checkpoint inhibitors have become important components of systemic treatment.

As with other VEGF-targeted therapies, axitinib requires monitoring for adverse events, including hypertension, diarrhea, fatigue, proteinuria and hepatic toxicity. Treatment decisions and dose modifications are guided by the prescribing information and individual patient tolerability.

What Does an Authorized Generic Mean for Patients?

Unlike a conventional generic medicine developed through a separate abbreviated new drug application, an authorized generic is the same drug product as its branded counterpart, marketed without the brand name.

According to the FDA, authorized generics are marketed under the original product’s approved new drug application and are considered therapeutically equivalent to the branded medicine.

For axitinib, the introduction of an authorized generic offers another commercial source of an existing treatment without requiring the development of a new clinical formulation or additional efficacy trials.

Importantly, the launch does not represent a new FDA approval or an expansion of axitinib’s clinical indications.

Authorized generics may be marketed at lower prices than branded medicines, although their actual effect on patient costs depends on pricing, insurance coverage, reimbursement arrangements and pharmacy availability.

Glenmark has not disclosed pricing information for its newly launched axitinib tablets.

A $538 Million US Market for Axitinib

The commercial significance of the launch is reflected in the existing US market for Inlyta.

According to IQVIA National Sales Perspectives data cited by Glenmark, Inlyta tablets generated approximately $538.4 million in US sales during the 12-month period ending September 2026, across retail and non-retail channels.

The figure highlights the established market for axitinib, although it does not indicate the potential revenue of Glenmark’s authorized generic or the extent of any future price reductions.

Commenting on the announcement, Marc Kikuchi, President and Business Head, North America at Glenmark, stated:

“The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to quality, affordable medicines for patients in the United States.”

The company described the launch as part of its efforts to expand its US pharmaceutical portfolio and address the needs of patients and healthcare providers.

Expanding Access to Established Cancer Treatments

The introduction of generic oncology medicines is an important part of the broader discussion surrounding treatment affordability and the sustainability of cancer care.

Although the development of new targeted agents and immunotherapies continues to reshape renal cell carcinoma treatment, access to established therapies remains equally relevant.

For patients with advanced kidney cancer, the availability of additional suppliers may create opportunities for greater market competition and potentially lower treatment costs. However, whether Glenmark’s authorized generic will translate into measurable savings for patients remains to be determined.

The November 2026 launch adds another option to the US axitinib market while maintaining the established clinical role of this VEGF-targeted therapy in advanced renal cell carcinoma.

Read further on OncoDaily: Belzutifan Plus Lenvatinib Moves Closer to EU Approval for Advanced Kidney Cancer
Belzutifan

Nare Hovhannisyan
Fact checked by Nare Hovhannisyan MD, Medical Writer
Aren Petrosyan
Medically reviewed by Aren Petrosyan MD, Editor at OncoDaily and Rankings and Analytics Lead of BIGR